Mostrar el registro sencillo del ítem
A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
| dc.rights.license | open | en_US |
| dc.contributor.author | NIELAND, Kaspar | |
| dc.contributor.author | LABBE, Antoine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SCHWEITZER, Cedric
ORCID: 0000-0002-2162-9479 IDREF: 133631583 | |
| dc.contributor.author | GICQUEL, Gaetan | |
| dc.contributor.author | KLEINTJENS, Joris | |
| dc.contributor.author | OSTAWAL, Amrita | |
| dc.contributor.author | TREUR, Maarten | |
| dc.contributor.author | FALVEY, Heather | |
| dc.date.accessioned | 2021-08-23T09:51:26Z | |
| dc.date.available | 2021-08-23T09:51:26Z | |
| dc.date.issued | 2021-06-10 | |
| dc.identifier.issn | 1932-6203 (Electronic) 1932-6203 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/110189 | |
| dc.description.abstractEn | OBJECTIVE: To investigate the cost-effectiveness of implementing iStent inject trabecular bypass stent (TBS) in conjunction with cataract surgery (Cat Sx) in patients with mild-to-moderate glaucoma from a societal perspective in France. The secondary objective was to explore the economic impact of iStent inject TBS in patients who comply to different degrees with their anti-glaucoma medications. METHODS: A previously published Markov model was adapted to estimate the cost-effectiveness of treatment with iStent inject TBS + Cat Sx versus Cat Sx alone over a lifetime time horizon in patients with mild-to-moderate open-angle glaucoma in France. Progression was modeled by health states reflecting increasing stages of vision loss. Disease progression was obtained from the two-year randomized clinical trial assessing safety and effectiveness of both interventions. French specific health-state utilities and costs were obtained through a targeted literature review. Model structure and inputs were validated by French ophthalmologists. Outcomes were expressed as incremental cost per quality-adjusted life-year (QALY) gained. The robustness of results was tested through sensitivity analyses. RESULTS: iStent inject TBS + Cat Sx reduced the number of medications needed and risk of blindness. Incremental cost and QALYs were euro75 and 0.065 leading to an incremental cost-effectiveness ratio (ICER) of euro1,154/QALY gained. ICER ranged from dominating for non-persistent patients to euro31,127 patients fully persistent with their medication regime. Results from one-way sensitivity analysis had a maximum ICER of euro29,000 when varying input parameters. iStent inject TBS + Cat Sx had an 86% chance of being cost-effective at a willingness-to-pay threshold of euro30,000 per QALY gained. CONCLUSION: Results demonstrate that iStent inject TBS + Cat Sx is a cost-effective intervention for intraocular pressure reduction when compared to Cat Sx alone in France. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title.en | A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1371/journal.pone.0252130 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34111130 | en_US |
| bordeaux.journal | PLoS ONE | en_US |
| bordeaux.page | e0252130 | en_US |
| bordeaux.volume | 16 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 6 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03324096 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-08-23T09:51:30Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20ONE&rft.date=2021-06-10&rft.volume=16&rft.issue=6&rft.spage=e0252130&rft.epage=e0252130&rft.eissn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.issn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.au=NIELAND,%20Kaspar&LABBE,%20Antoine&SCHWEITZER,%20Cedric&GICQUEL,%20Gaetan&KLEINTJENS,%20Joris&rft.genre=article |
